Index RUT
P/E 30.69
EPS (ttm) 3.49
Insider Own 0.93%
Shs Outstand 45.51M
Perf Week 11.76%
Market Cap 4.91B
Forward P/E 23.91
EPS next Y 4.48
Insider Trans -8.64%
Shs Float 45.44M
Perf Month 16.94%
Income 160.48M
PEG 1.18
EPS next Q 0.95
Inst Own 97.55%
Short Float 3.29%
Perf Quarter 45.77%
Sales 2.28B
P/S 2.15
EPS this Y 19.44%
Inst Trans 1.48%
Short Ratio 3.14
Perf Half Y 88.23%
Book/sh 29.76
P/B 3.60
EPS next Y 11.51%
ROA 6.27%
Short Interest 1.49M
Perf Year 98.09%
Cash/sh 6.55
P/C 16.33
EPS next 5Y 26.00%
ROE 12.66%
52W Range 53.49 - 100.95
Perf YTD 41.72%
Dividend Est. -
P/FCF 36.35
EPS past 5Y -
ROI 8.67%
52W High 6.00%
Beta 1.44
Dividend TTM -
Quick Ratio 1.40
Sales past 5Y -1.00%
Gross Margin 32.64%
52W Low 100.06%
ATR (14) 3.46
Dividend Ex-Date -
Current Ratio 1.90
EPS Y/Y TTM 806.64%
Oper. Margin 9.21%
RSI (14) 75.95
Volatility 5.16% 3.07%
Employees 5859
Debt/Eq 0.36
Sales Y/Y TTM 25.77%
Profit Margin 7.03%
Recom 1.87
Target Price 111.73
Option/Short Yes / Yes
LT Debt/Eq 0.36
EPS Q/Q 526.82%
Payout 0.00%
Rel Volume 2.56
Prev Close 99.82
Sales Surprise 4.13%
EPS Surprise 47.88%
Sales Q/Q 22.00%
Earnings May 02 BMO
Avg Volume 476.31K
Price 107.01
SMA20 15.74%
SMA50 17.66%
SMA200 45.05%
Trades
Volume 1,217,757
Change 7.20%
Date
Action
Analyst
Rating Change
Price Target Change
May-03-24 Reiterated
TD Cowen
Buy
$110 → $115
Mar-13-24 Reiterated
TD Cowen
Outperform
$107 → $110
Feb-27-24 Upgrade
Robert W. Baird
Neutral → Outperform
$68 → $108
Feb-27-24 Upgrade
Canaccord Genuity
Hold → Buy
$68 → $105
Jan-19-24 Upgrade
Oppenheimer
Perform → Outperform
$81
Jan-04-24 Downgrade
Raymond James
Outperform → Mkt Perform
Dec-19-23 Upgrade
Piper Sandler
Neutral → Overweight
$72 → $91
Dec-12-23 Upgrade
JP Morgan
Underweight → Neutral
$68
Dec-05-23 Initiated
ROTH MKM
Buy
$82
Dec-01-23 Resumed
Canaccord Genuity
Hold
$68
Sep-22-23 Initiated
Seaport Research Partners
Buy
$80
Sep-11-23 Initiated
Guggenheim
Neutral
Aug-18-23 Upgrade
Argus
Hold → Buy
$82
Jul-12-23 Downgrade
Raymond James
Strong Buy → Outperform
$70 → $81
Mar-03-23 Downgrade
JP Morgan
Neutral → Underweight
$53 → $50
Aug-08-22 Downgrade
JP Morgan
Overweight → Neutral
$65
Aug-05-22 Downgrade
Stephens
Overweight → Equal-Weight
$65 → $55
May-12-22 Initiated
Piper Sandler
Neutral
$51
Dec-20-21 Downgrade
Argus
Buy → Hold
Nov-08-21 Downgrade
Piper Sandler
Overweight → Neutral
$90 → $84
Show Previous Ratings
May-03-24 11:36AM
08:39AM
06:37AM
03:36AM
May-02-24 01:54PM
11:19AM
Loading…
11:19AM
10:44AM
(Investor's Business Daily)
10:00AM
09:53AM
09:45AM
08:44AM
(Associated Press Finance)
08:30AM
Apr-30-24 06:00PM
09:50AM
Apr-29-24 11:58AM
08:38AM
Loading…
08:38AM
04:21AM
Apr-28-24 08:00PM
Apr-25-24 10:01AM
Apr-18-24 11:15AM
Apr-15-24 12:10PM
Apr-11-24 04:05PM
Apr-10-24 08:37AM
Apr-09-24 08:00PM
Mar-27-24 11:30AM
Mar-25-24 09:50AM
Mar-21-24 08:48AM
Mar-20-24 09:14AM
Mar-19-24 06:00PM
08:45AM
09:07AM
Loading…
Mar-15-24 09:07AM
Mar-11-24 08:28AM
Mar-08-24 01:31AM
Mar-07-24 08:45AM
Mar-06-24 09:41AM
07:00AM
Mar-05-24 12:00PM
09:00AM
Mar-03-24 08:33AM
Mar-01-24 09:40AM
09:15AM
Feb-29-24 12:20PM
Feb-28-24 09:18AM
Feb-27-24 11:02AM
08:45AM
12:59AM
(Thomson Reuters StreetEvents)
Feb-26-24 10:00AM
09:45AM
09:19AM
08:57AM
08:51AM
08:50AM
(Associated Press Finance)
08:30AM
Feb-23-24 11:02AM
08:45AM
Feb-22-24 10:57AM
08:45AM
Feb-21-24 08:45AM
07:26AM
Feb-20-24 08:45AM
Feb-19-24 04:05PM
10:00AM
Feb-15-24 08:45AM
Feb-14-24 04:05PM
12:10PM
08:45AM
Feb-13-24 08:45AM
Jan-31-24 08:45AM
Jan-23-24 09:40AM
Jan-22-24 04:05PM
Jan-18-24 04:05PM
Jan-10-24 08:24AM
Jan-08-24 09:21AM
Dec-18-23 06:48AM
Dec-08-23 09:40AM
Dec-05-23 05:16AM
Dec-04-23 12:20PM
Dec-01-23 12:00PM
Nov-18-23 12:00AM
(Thomson Reuters StreetEvents)
Nov-16-23 06:19AM
Nov-15-23 08:45AM
Nov-14-23 09:40AM
Nov-07-23 07:03PM
(Investor's Business Daily)
Nov-06-23 03:34PM
09:50AM
Nov-03-23 12:20PM
11:39AM
08:36AM
Nov-02-23 09:55AM
08:43AM
(Associated Press Finance)
08:30AM
Nov-01-23 01:10PM
Oct-31-23 12:44PM
Oct-30-23 12:22PM
12:12PM
12:07PM
Oct-27-23 12:03PM
Oct-26-23 04:05PM
12:10PM
11:30AM
Itron, Inc. is a technology and services company, which engages in the provision of solutions that measure, manage, and analyze energy and water use. It operates through the following segments: Device Solutions, Networked Solutions, and Outcomes. The Device Solutions segment includes hardware products used for measurement, control, or sensing that do not have communications capability embedded for use with its broader Itron systems. The Networked Solutions segment offers a combination of communicating devices, network infrastructure, and associated application software designed and sold as a complete solution for acquiring and transporting robust application-specific data. The Outcomes segment consist of the firm's value-added, enhanced software and services operating segment in which it manage, organize, analyze, and interpret data to improve decision making, maximize operational profitability, drive resource efficiency, and deliver results for consumers, utilities, and smart cities. The company was founded in 1977 and is headquartered in Liberty Lake, WA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Deitrich Thomas President & CEO Mar 25 '24 Option Exercise 35.13 8,538 299,940 207,036 Mar 26 03:32 PM Lande Jerome J. Director Mar 07 '24 Sale 95.25 14,896 1,418,895 5,750 Mar 07 06:47 PM Deitrich Thomas President & CEO Feb 28 '24 Sale 91.02 3,353 305,198 198,498 Feb 29 02:17 PM Hooper Joan S SVP & CFO Feb 28 '24 Sale 91.02 1,790 162,930 73,348 Feb 29 02:54 PM Marcolini John F. SVP, Networked Solutions Feb 28 '24 Sale 91.02 636 57,890 15,803 Feb 29 02:58 PM Reeves Donald L. III SVP, Outcomes Feb 28 '24 Sale 91.02 502 45,693 16,427 Feb 29 03:31 PM Patrick Justin K SVP, Device Solutions Feb 28 '24 Sale 91.02 305 27,762 20,623 Feb 29 03:27 PM Ware Christopher E. VP, General Counsel & Corp Sec Feb 28 '24 Sale 91.02 136 12,379 15,682 Feb 29 03:33 PM Pulatie-Hahn Laurie Ann SVP, HR Feb 28 '24 Sale 91.02 92 8,374 18,831 Feb 29 03:29 PM Deitrich Thomas President & CEO Feb 27 '24 Sale 92.20 3,311 305,259 201,851 Feb 29 02:17 PM Hooper Joan S SVP & CFO Feb 27 '24 Sale 92.20 1,766 162,817 75,138 Feb 29 02:54 PM Marcolini John F. SVP, Networked Solutions Feb 27 '24 Sale 92.20 626 57,714 16,439 Feb 29 02:58 PM Reeves Donald L. III SVP, Outcomes Feb 27 '24 Sale 92.20 496 45,729 16,929 Feb 29 03:31 PM Patrick Justin K SVP, Device Solutions Feb 27 '24 Sale 92.20 301 27,751 20,928 Feb 29 03:27 PM Ware Christopher E. VP, General Counsel & Corp Sec Feb 27 '24 Sale 92.20 159 14,659 15,818 Feb 29 03:33 PM Pulatie-Hahn Laurie Ann SVP, HR Feb 27 '24 Sale 92.20 100 9,220 18,923 Feb 29 03:29 PM Deitrich Thomas President & CEO Feb 26 '24 Sale 87.10 3,362 292,822 205,162 Feb 27 05:55 PM Hooper Joan S SVP & CFO Feb 26 '24 Sale 87.10 1,869 162,785 76,904 Feb 27 05:57 PM Marcolini John F. SVP, Networked Solutions Feb 26 '24 Sale 87.10 677 58,965 17,065 Feb 27 05:59 PM Reeves Donald L. III SVP, Outcomes Feb 26 '24 Sale 87.10 536 46,684 17,425 Feb 27 06:07 PM Patrick Justin K SVP, Device Solutions Feb 26 '24 Sale 87.10 339 29,526 21,229 Feb 27 06:01 PM Ware Christopher E. VP, General Counsel & Corp Sec Feb 26 '24 Sale 87.10 168 14,632 15,977 Feb 27 06:09 PM Pulatie-Hahn Laurie Ann SVP, HR Feb 26 '24 Sale 87.10 106 9,232 19,023 Feb 27 06:06 PM Deitrich Thomas President & CEO Feb 20 '24 Sale 75.37 1,912 144,115 169,073 Feb 21 02:02 PM Hooper Joan S SVP & CFO Feb 20 '24 Sale 75.37 1,560 117,583 60,141 Feb 21 02:05 PM Marcolini John F. SVP, Networked Solutions Feb 20 '24 Sale 75.37 511 38,516 8,581 Feb 21 02:07 PM Reeves Donald L. III SVP, Outcomes Feb 20 '24 Sale 75.37 383 28,868 8,708 Feb 21 02:14 PM Patrick Justin K SVP, Device Solutions Feb 20 '24 Sale 75.37 278 20,954 13,408 Feb 21 02:09 PM Pulatie-Hahn Laurie Ann SVP, HR Feb 20 '24 Sale 75.37 127 9,572 13,791 Feb 21 02:11 PM Marcolini John F. SVP, Networked Solutions Sep 12 '23 Sale 63.10 299 18,867 9,092 Sep 13 03:04 PM Marcolini John F. SVP, Networked Solutions Sep 11 '23 Sale 63.60 171 10,875 9,391 Sep 12 04:38 PM Reeves Donald L. III SVP, Outcomes Jul 31 '23 Option Exercise 63.16 983 62,084 10,074 Aug 01 02:28 PM Reeves Donald L. III SVP, Outcomes Jul 31 '23 Sale 78.00 983 76,674 9,091 Aug 01 02:28 PM Reeves Donald L. III SVP, Outcomes Jun 06 '23 Option Exercise 55.49 4,802 266,444 15,622 Jun 07 02:31 PM Reeves Donald L. III SVP, Outcomes Jun 06 '23 Sale 70.59 6,531 461,017 9,091 Jun 07 02:31 PM Ware Christopher E. VP, General Counsel & Corp Sec May 15 '23 Sale 66.19 194 12,841 10,140 May 16 03:26 PM Ware Christopher E. VP, General Counsel & Corp Sec May 12 '23 Sale 66.66 260 17,332 10,334 May 15 03:51 PM
Index RUT
P/E 27.48
EPS (ttm) 2.61
Insider Own 0.52%
Shs Outstand 30.77M
Perf Week 9.09%
Market Cap 2.21B
Forward P/E 13.06
EPS next Y 5.50
Insider Trans -0.31%
Shs Float 30.64M
Perf Month -7.86%
Income 82.35M
PEG 1.13
EPS next Q 0.91
Inst Own 116.32%
Short Float 12.71%
Perf Quarter -11.31%
Sales 1.26B
P/S 1.76
EPS this Y 24.46%
Inst Trans 2.19%
Short Ratio 6.95
Perf Half Y -27.31%
Book/sh 27.76
P/B 2.59
EPS next Y 28.01%
ROA 3.56%
Short Interest 3.89M
Perf Year -43.28%
Cash/sh 1.10
P/C 65.29
EPS next 5Y 24.40%
ROE 10.25%
52W Range 61.05 - 138.47
Perf YTD -34.47%
Dividend Est. 0.80 (1.11%)
P/FCF 15.62
EPS past 5Y 7.64%
ROI 4.46%
52W High -48.18%
Beta 1.42
Dividend TTM 0.80 (1.11%)
Quick Ratio 1.08
Sales past 5Y 8.21%
Gross Margin 51.39%
52W Low 17.54%
ATR (14) 2.73
Dividend Ex-Date Mar 14, 2024
Current Ratio 2.18
EPS Y/Y TTM 183.55%
Oper. Margin 11.14%
RSI (14) 47.41
Volatility 3.56% 3.64%
Employees 4000
Debt/Eq 1.16
Sales Y/Y TTM 15.95%
Profit Margin 6.55%
Recom 1.88
Target Price 92.38
Option/Short Yes / Yes
LT Debt/Eq 1.16
EPS Q/Q 980.96%
Payout 39.15%
Rel Volume 0.83
Prev Close 70.12
Sales Surprise 1.80%
EPS Surprise 7.06%
Sales Q/Q 5.68%
Earnings Apr 24 AMC
Avg Volume 560.64K
Price 71.76
SMA20 -1.12%
SMA50 -6.87%
SMA200 -26.35%
Trades
Volume 467,637
Change 2.34%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-01-24 Reiterated
Needham
Buy
$119 → $129
May-22-23 Initiated
CL King
Buy
$140
Mar-27-23 Upgrade
KeyBanc Capital Markets
Sector Weight → Overweight
$124
Mar-21-23 Initiated
Wells Fargo
Equal Weight
$96
Oct-12-22 Initiated
Jefferies
Hold
$85
Mar-02-22 Resumed
BofA Securities
Neutral
$155
Oct-06-21 Upgrade
Needham
Hold → Buy
$150
Jul-15-21 Initiated
UBS
Buy
$160
May-25-21 Initiated
Barclays
Overweight
$175
Nov-26-19 Downgrade
Needham
Buy → Hold
Nov-12-19 Initiated
JP Morgan
Overweight
$136
Oct-31-19 Reiterated
Needham
Buy
$111 → $115
Oct-04-19 Reiterated
Needham
Buy
$101 → $110
Aug-22-19 Upgrade
Piper Jaffray
Neutral → Overweight
$88 → $110
Apr-18-19 Initiated
Stifel
Buy
$95
Apr-16-19 Reiterated
Needham
Buy
$87 → $94
Jan-23-19 Reiterated
Needham
Buy
$86 → $79
Oct-16-18 Initiated
Barclays
Equal Weight
$78
Aug-07-18 Reiterated
Needham
Buy
$83 → $88
Aug-02-18 Reiterated
Needham
Buy
$73 → $83
Show Previous Ratings
May-02-24 05:00PM
May-01-24 04:05PM
Apr-26-24 08:36AM
Apr-25-24 12:44PM
10:34AM
03:23AM
Loading…
03:23AM
Apr-24-24 07:00PM
05:40PM
05:15PM
04:14PM
(Associated Press Finance)
04:05PM
04:03PM
Apr-10-24 12:27PM
Apr-03-24 09:09AM
Apr-02-24 04:05PM
07:34AM
Loading…
Mar-30-24 07:34AM
Mar-25-24 06:00PM
Mar-19-24 09:33AM
Mar-05-24 07:32AM
Feb-27-24 04:05PM
Feb-02-24 10:07AM
Feb-01-24 12:58PM
10:39AM
Jan-31-24 06:00PM
05:20PM
04:30PM
(Associated Press Finance)
04:05PM
Jan-30-24 09:15AM
Jan-15-24 09:10AM
Jan-03-24 04:05PM
04:05PM
Loading…
Dec-21-23 04:05PM
Dec-15-23 07:25AM
Dec-07-23 01:05PM
Dec-05-23 04:05PM
Nov-24-23 11:31AM
Nov-16-23 08:12AM
Nov-13-23 04:05PM
Oct-31-23 04:05PM
Oct-30-23 01:42AM
Oct-27-23 02:28PM
Oct-26-23 11:40AM
10:08AM
09:02AM
(Thomson Reuters StreetEvents)
Oct-25-23 08:30PM
05:40PM
05:32PM
04:36PM
(Associated Press Finance)
04:05PM
Oct-19-23 09:40AM
Oct-04-23 04:05PM
Sep-26-23 11:40AM
09:40AM
Sep-25-23 09:37AM
Sep-16-23 01:01PM
Sep-05-23 04:05PM
Aug-28-23 11:43AM
Aug-25-23 08:02AM
Aug-24-23 04:05PM
08:47AM
Aug-10-23 04:05PM
Jul-29-23 08:44AM
Jul-27-23 10:33AM
Jul-26-23 09:00PM
05:35PM
04:30PM
04:05PM
Jul-12-23 09:57AM
Jul-05-23 04:05PM
Jun-28-23 10:19AM
Jun-21-23 08:00PM
02:38PM
Jun-20-23 11:44AM
Jun-19-23 12:00PM
05:47AM
Jun-16-23 10:31AM
Jun-15-23 09:58AM
07:28AM
07:22AM
Jun-02-23 11:35AM
May-25-23 04:05PM
May-24-23 04:05PM
11:40AM
May-19-23 10:31AM
09:17AM
May-18-23 11:52AM
May-15-23 12:25PM
May-12-23 06:04AM
May-08-23 02:06PM
Apr-27-23 08:12AM
(Thomson Reuters StreetEvents) +12.33%
06:11AM
Apr-26-23 08:00PM
05:45PM
04:05PM
Apr-25-23 11:40AM
Apr-11-23 01:23PM
Apr-04-23 04:05PM
12:46PM
Mar-22-23 04:05PM
Mar-15-23 06:40AM
Mar-14-23 04:05PM
CONMED Corp. is a medical technology company, which engages in providing devices and equipment for surgical procedures. Its products include AirSeal and insufflation, allograft cartilage and tissue, arthroplasty, biliary and endoscopic ultrasound, biomedical sensors and electrodes, biopsy and polypectomy, dilators and accessories, electrosurgical units, fixation devices, hemostasis, implants and suture anchors, infection prevention, patient positioning, and related products. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Beyer Pat Chief Operating Officer Apr 30 '24 Buy 68.30 3,000 204,900 10,807 May 02 01:03 PM Cohen Heather L EVP & Chief HR & Legal Officer Mar 08 '24 Option Exercise 68.91 52,500 3,617,900 59,612 Mar 11 04:42 PM Lalomia Brent Vice President QA and RA Mar 07 '24 Option Exercise 0.00 75 0 983 Mar 11 11:44 AM Peters Stanley W III President AS and AET Dec 04 '23 Option Exercise 41.93 2,300 96,439 2,363 Dec 06 12:12 PM Peters Stanley W III President AS and AET Dec 04 '23 Sale 109.93 2,300 252,833 63 Dec 06 12:12 PM Peters Stanley W III President AS and AET Nov 07 '23 Option Exercise 41.93 1,200 50,316 1,263 Nov 09 01:42 PM Peters Stanley W III President AS and AET Nov 07 '23 Sale 102.39 1,200 122,874 63 Nov 09 01:42 PM Peters Stanley W III President AS and AET Sep 13 '23 Option Exercise 41.93 2,000 83,860 2,063 Sep 15 05:38 PM Peters Stanley W III President AS and AET Sep 13 '23 Sale 107.31 2,000 214,629 63 Sep 15 05:38 PM Garner Todd W Executive Vice President & CFO Aug 16 '23 Sale 112.00 1,355 151,760 0 Aug 17 06:26 PM Lalomia Brent Vice President QA and RA Jun 17 '23 Option Exercise 0.00 250 0 979 Jun 21 06:35 PM Hartman Curt R President, CEO and Chair Jun 15 '23 Sale 136.00 1,000 136,000 4,299 Jun 16 04:31 PM SHAGORY PETER K EVP, STRAT & CORP DEVT Jun 09 '23 Option Exercise 55.42 4,500 249,390 6,361 Jun 12 04:52 PM Peters Stanley W III VP GM Advanced Surgery Jun 08 '23 Option Exercise 41.93 5,000 209,650 5,063 Jun 09 04:40 PM Ferrell John D. Executive Vice President - HR Jun 08 '23 Option Exercise 41.93 1,700 71,281 2,402 Jun 09 04:39 PM Peters Stanley W III VP GM Advanced Surgery Jun 08 '23 Sale 131.14 5,000 655,676 63 Jun 09 04:40 PM Ferrell John D. Executive Vice President - HR Jun 08 '23 Sale 131.81 1,700 224,077 702 Jun 09 04:39 PM CONCANNON BRIAN Director Jun 07 '23 Sale 129.01 812 104,756 9,335 Jun 08 04:39 PM Workman John L Director Jun 01 '23 Option Exercise 0.00 335 0 20,110 Jun 02 05:45 PM Schwarzentraub Barbara J Director Jun 01 '23 Option Exercise 0.00 335 0 3,563 Jun 02 05:42 PM Lande Jerome J. Director Jun 01 '23 Option Exercise 0.00 335 0 3,554 Jun 02 05:40 PM Farkas Charles Director Jun 01 '23 Option Exercise 0.00 335 0 19,578 Jun 02 05:37 PM Council LaVerne H Director Jun 01 '23 Option Exercise 0.00 335 0 3,267 Jun 02 05:32 PM CONCANNON BRIAN Director Jun 01 '23 Option Exercise 0.00 335 0 10,147 Jun 02 05:28 PM BRONSON DAVID M Director Jun 01 '23 Option Exercise 0.00 335 0 15,110 Jun 02 05:26 PM Aronson Martha Goldberg Director Jun 01 '23 Option Exercise 0.00 335 0 11,610 Jun 02 05:24 PM Peters Stanley W III VP GM Advanced Surgery May 22 '23 Option Exercise 41.93 1,500 62,895 1,563 May 23 04:55 PM Peters Stanley W III VP GM Advanced Surgery May 22 '23 Sale 120.89 1,500 181,342 63 May 23 04:55 PM Peters Stanley W III VP GM Advanced Surgery May 18 '23 Option Exercise 41.93 1,500 62,895 1,563 May 19 04:06 PM Peters Stanley W III VP GM Advanced Surgery May 18 '23 Sale 119.24 1,500 178,861 63 May 19 04:06 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite